Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma north Japan lung cancer group study 0803

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages 1805-1809

  Inoue, Akira ^a   Sugawara, Shunichi ^b   Harada, Masao ^c   Kobayashi, Kunihiko ^d   Kozuki, Toshiyuki ^e   Kuyama, Shoichi ^f   Maemondo, Makoto ^g   Asahina, Hajime ^h   Hisamoto, Akiko ⁱ   Nakagawa, Taku ^j   Hotta, Katsuyuki ⁱ   Nukiwa, Toshihiro ^k  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b SENDAI KOUSEI HOSPITAL   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d SAITAMA UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f Iwakuni Medical Center   (Japan)

^g Miyagi Cancer Center   (Japan)

^h HOKKAIDO UNIVERSITY   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j Senboku Kumiai General Hospital   (Japan)

^k South Miyagi Medical Center   (Japan)

more..

Author keywords

Amrubicin; Chemotherapy; Invasive thymoma; Phase II; Thymic carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; AMRUBICIN; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CORTICOSTEROID; HEMOGLOBIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CARDIOTOXICITY; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; THYMOMA; THYMUS CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; JAPAN; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; THYMUS NEOPLASMS;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; THYMOMA; THYMUS NEOPLASMS;

EID: 84927612318     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000362     Document Type: Article

References (16)

1. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR Jr. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-664.
2. NCCN Clinical Practice Guidelines in Oncology. Thymomas and thymic carcinomas. version I. 2014; available from http://www.nccn.org/professionals/physician-gls/pdf/thymic.pdf; Internet; accessed 27 Feb. 2014.
3. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164-1168.
4. Yana T, Negoro S, Takada M, et al; West Japan Thoracic Oncology Group. Phase II study of amrubicin in previously untreated patients with extensivedisease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258.
5. Inoue A, Yamazaki K, Maemondo M, et al. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol 2006;1:551-555.
6. Inoue A, Ishimoto O, Fukumoto S, et al. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol 2010;21:800-803.
7. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30-33.
8. Schmitt J, Loehrer PJ Sr. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010;5(10 Suppl 4):S357-S360.
9. Yoh K, Goto K, Ishii G, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003;98:926-931.
10. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011;29:2060-2065.
11. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30; 2055-62, 2012.
12. Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 2011;74:492-496.
13. Okuma Y, Hosomi Y, Takagi Y, et al. Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 2013;80:75-80.
14. Force J, Rajan A, Dombi E, Steinberg SM, Giaccone G. Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. J Thorac Oncol 2011;6:1267-1273.
15. Marx A, Strobel PH, Zettl A, et al. World Health Organization classification of tumors. In Travis WD, Brambilla E, Muller-Hermelink HK, et al (eds.). Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004 [Chapter 3].
16. Kawashima Y, Inoue A, Sugawara S, et al. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. Respir Investig 2014;52:190-194.